4-氯-3-乙烯基吡啶 | 223573-95-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 4-氯-3-乙烯基吡啶
• 英文名称: 4-chloro-3-vinylpyridine
• 英文别名: 4-chloro-3-ethenylpyridine
• CAS: 223573-95-3
• 化学式: C₇H₆ClN
• 分子量: 139.584
• InChiKey: YDFKANAGZKTFRJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-氯-3-乙烯基吡啶 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 三乙胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 生成 (S)-2-({5-[(E)-2-(4-Methoxy-pyridin-3-yl)-vinyl]-2'-methyl-biphenyl-2-carbonyl}-amino)-4-methylsulfanyl-butyric acid methyl ester
  参考文献：
  名称：

  Potent inhibitors of protein farnesyltransferase: Heteroarenes as cysteine replacements

  摘要：

  Synthesis and biological evaluation of heteroarenes as reduced cysteine replacements are described. Of the heteroaryl groups examined with respect to FT inhibitor FTI-276 (1), pyridyl was the replacement found to be most effective. Substitutions at C4 of the pyridyl moiety did not affect the in vitro activity. Compound 9a was found to have moderate in vivo bioavailability.

  DOI：

  10.1016/s0960-894x(99)00080-3
• 作为产物：
  描述：

  4-氯吡啶 在 叔丁基锂 、 lithium diisopropyl amide 作用下， 以 乙醚 、 正戊烷 为溶剂， 反应 4.0h， 生成 4-氯-3-乙烯基吡啶
  参考文献：
  名称：

  Aromatizing Olefin Metathesis by Ligand Isolation inside a Metal– Organic Framework

  摘要：

  The aromatizing ring-closing metathesis has been shown to take place inside an extended porous framework. Employing a combination of solvent-assisted linker exchange and postsynthesis modification using olefin metathesis, the noninterpenetrated SALEM-14 was formed and converted catalytically into PAH-MOF-1 with polycyclic aromatic hydrocarbon (PAR) pillars. The metal-organic framework in SALEM-14 prevents "inter-molecular" olefin metathesis from occurring between the pillars in the presence of the first generation Hoveyda-Grubbs catalyst, while favoring the production of a PAH, which can be released from the framework under acidic conditions in dimethylsulfoxide.

  DOI：

  10.1021/ja407333q

文献信息

• Inhibitors of protein isoprenyl transferases
  申请人：University of Pittsburgh

  公开号：US20020193596A1

  公开（公告）日：2002-12-19

  Compounds having the formula 1 or a pharmaceutically acceptable salt thereof wherein R 1 is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L 2 —, and (i) heterocyclic-L 2 —; R 2 is selected from (a) 2 (b) —C(O)NH—CH(R 14 )—C(O)OR 15 , (c) 3 (d) —C(O)NH—CH(R 14 )—C(O)NHSO 2 R 16 (e) —C(O)NH—CH(R 14 )-tetrazolyl, (f) —C(O)NH-heterocyclic, and (g) —C(O)NH—CH(R 14 )—C(O)NR 17 R 18 ; R 3 is heterocyclic, aryl, substituted or unsubstituted cycloalkyl; R 4 is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L 1 is absent or is selected from (a) —L 4 —N(R 5 )—L 5 —, (b) —L 4 —O—L 5 —, (c) —L 4 —S(O) n —L 5 — (d) —L 4 -L 6 —C(W)—N(R 5 )—L 5 —, (e) —L 4 -L 6 —S(O) m —N(R 5 )—L 5 —, (f) —L 4 —N(R 5 )—C(W)—L 7 -L 5 —, (g) —L 4 —N(R 5 )—S(O) p —L 7 —L 5 —, (h) optionally substituted alkylene, (i) optionally substituted alkenylene, and (j) optionally substituted alkynylene are inhibitors of protein isoprenyl transferases. Also disclosed are protein isoprenyl transferase inhibiting compositions and a method of inhibiting protein isoprenyl transferases.

  具有以下公式的化合物或其药学上可接受的盐，其中R1为(a)氢，(b)较低的烷基，(c)烯基，(d)烷氧基，(e)硫代烷氧基，(f)卤素，(g)卤代烷基，(h)芳基-L2—，以及(i)杂环-L2—；R2从(a)中选择，(b) -C(O)NH-CH(R14)-C(O)OR15，(c)中选择，(d) -C(O)NH-CH(R14)-C(O)NHSO2R16，(e) -C(O)NH-CH(R14)-四唑基，(f) -C(O)NH-杂环，以及(g) -C(O)NH-CH(R14)-C(O)NR17R18；R3为杂环，芳基，取代或未取代的环烷基；R4为氢，较低烷基，卤代烷基，卤素，芳基，芳基烷基，杂环基，或(杂环)烷基；L1为空缺或从(a) -L4-N(R5)-L5-，(b) -L4-O-L5-，(c) -L4-S(O)n-L5-，(d) -L4-L6-C(W)-N(R5)-L5-，(e) -L4-L6-S(O)m-N(R5)-L5-，(f) -L4-N(R5)-C(W)-L7-L5-，(g) -L4-N(R5)-S(O)p-L7-L5-，(h)可选择取代的烷基，(i)可选择取代的烯基，以及(j)可选择取代的炔基是蛋白异戊二烯转移酶的抑制剂。还公开了蛋白异戊二烯转移酶抑制组合物和抑制蛋白异戊二烯转移酶的方法。
• [EN] MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE MÉTALLOPROTÉINASE MATRICIELLE (MMP) ET LEURS PROCÉDÉS D'UTILISATION
  申请人：FORESEE PHARMACEUTICALS CO LTD

  公开号：WO2021097190A1

  公开（公告）日：2021-05-20

  Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

  基于噻唑烷二酮的化合物被描述为抑制基质金属蛋白酶（MMPs），特别是巨噬细胞弹性蛋白酶（MMP-12）的有效化合物。还描述了相关的组合物和使用这些化合物抑制MMP-12并治疗由MMP-12介导的疾病的方法，如哮喘、慢性阻塞性肺病（COPD）、肺气肿、急性肺损伤、特发性肺纤维化（IPF）、结节病、系统性硬化、肝纤维化、非酒精性脂肪性肝炎（NASH）、关节炎、癌症、心脏病、炎症性肠病（IBD）、急性肾损伤（AKI）、慢性肾病（CKD）、Alport综合征和肾炎。
• US6693123B2
  申请人：——

  公开号：US6693123B2

  公开（公告）日：2004-02-17
• Potent inhibitors of protein farnesyltransferase: Heteroarenes as cysteine replacements
  作者：Wang Shen、Stephen Fakhoury、Greg Donner、Kenneth Henry、Jang Lee、Haichao Zhang、Jerry Cohen、Robert Warner、Badr Saeed、Sajeev Cherian、Stephen Tahir、Peter Kovar、Joy Bauch、Shi-Chung Ng、Kennan Marsh、Hing Sham、Saul Rosenberg

  DOI：10.1016/s0960-894x(99)00080-3

  日期：1999.3

  Synthesis and biological evaluation of heteroarenes as reduced cysteine replacements are described. Of the heteroaryl groups examined with respect to FT inhibitor FTI-276 (1), pyridyl was the replacement found to be most effective. Substitutions at C4 of the pyridyl moiety did not affect the in vitro activity. Compound 9a was found to have moderate in vivo bioavailability.
• Aromatizing Olefin Metathesis by Ligand Isolation inside a Metal– Organic Framework
  作者：Nicolaas A. Vermeulen、Olga Karagiaridi、Amy A. Sarjeant、Charlotte L. Stern、Joseph T. Hupp、Omar K. Farha、J. Fraser Stoddart

  DOI：10.1021/ja407333q

  日期：2013.10.9

  The aromatizing ring-closing metathesis has been shown to take place inside an extended porous framework. Employing a combination of solvent-assisted linker exchange and postsynthesis modification using olefin metathesis, the noninterpenetrated SALEM-14 was formed and converted catalytically into PAH-MOF-1 with polycyclic aromatic hydrocarbon (PAR) pillars. The metal-organic framework in SALEM-14 prevents "inter-molecular" olefin metathesis from occurring between the pillars in the presence of the first generation Hoveyda-Grubbs catalyst, while favoring the production of a PAH, which can be released from the framework under acidic conditions in dimethylsulfoxide.